How much does Ariad's management/BoD of TC's science suck?
Over yonder the science guys have been raising some interesting points. Poster medichem has insights on the structure of '788, comparing it favorably to Astra Zeneca's Tagrisso/Osimertinib/AZD9291 drug.
As I reported from the 2014 AGM when I had a long talk afterwards with TC, he is all about the science and his methods to address mutations. '788 is in that category, as is '113. As is Pona, but the latter drugs are looking cleaner.
But Ariad has done everything wrong with the drugs once they go into the clinic. Blame HB, his cronies, the totally inept, incompetent BoD and their damage is proving to be catastrophic.
AZD9291 went from day 1 in the clinic to 'on the market' in 2 1/2 years. That would mean '788 on the market in late 2018 if Astra Zeneca owned it. But they don't, yet anyway. By comparison, '113, with the same good cred AZD9291 has, will have taken 5 years to market, 2+ year late, as I have often complained. Ariad management sucks, period.
And people wonder why I and others have been focused on trying so hard to oust Ariad's management. Go figure.
The BoD overpaid themselves and the CEO, they breached their fiduciary responsibilities, they doctored their records and coerced and bought off their accuser...I want THE TRUTH!!!
